Top Markets
#1 Black Phoenix Black Phoenix +736.30%
#2 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +24.93%
#3 Wrapped STX (Velar) Wrapped STX (Velar) +17.76%
#4 MetaDAO MetaDAO +16.19%
#5 Verus Coin Verus Coin +13.95%
#6 Akedo Akedo +10.21%
#7 PondCoin PondCoin +6.99%
#8 wojak wojak +6.93%
#9 Quack AI Quack AI +6.35%
#10 MiL.k Alliance MiL.k Alliance +6.08%
Coin of the day
Black Phoenix Black Phoenix
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

2315
Classifica tra le azioni #4862
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., established in 2009 with its... Biocytogen Pharmaceuticals (Beijing) Co., Ltd., established in 2009 with its main office in Beijing, China, operates as a global biotechnology firm. Its core business involves the international research and development of antibody-based treatments. The company's drug development portfolio currently features a dozen key product candidates; specifically, two are actively progressing through multi-regional Phase II clinical trials, while another pair is in Phase I clinical assessments. Their therapeutic focus spans critical health areas such as oncology, autoimmune disorders, inflammatory conditions, metabolic diseases, and other ailments. Supporting these pharmaceutical ventures, the broader Beijing Biocytogen Co., Ltd. group, which commenced operations in 2008, also in Beijing, specializes in the creation and large-scale distribution of genetically modified animal models. This group provides comprehensive preclinical research services, leveraging its expertise in advanced gene-humanized models, patient-derived xenograft (PDX) models, and human immune system reconstituted models. Their extensive catalog includes a diverse array of specialized gene-edited mice and rats – for example, B-NDG mice, various Cre and knockout (KO) lines (like B-p53 KO and B-ApoE KO), knock-in (KI) models, B-hFcgrt (FcRn) mice, in addition to genome-edited human embryonic stem cells (hESC) and luciferase-reporter stable tumor cell lines. Furthermore, this overarching Biocytogen entity has cultivated an advanced platform dedicated to antibody discovery and development. It offers specialized pharmacology services across vital domains including tumor immunology, general oncology, autoimmune research, and both in vivo and in vitro pharmacological evaluations. The group also makes its products accessible through online sales channels. Beyond its primary location in Beijing, China, the company maintains additional facilities in Haimen, Jiangsu, and Shanghai, China, as well alongside international branches in Heidelberg, Germany, and Boston, United States.
Prezzo delle azioni
$7.93
Ultima sincronizzazione: 2026-08-26
Capitalizzazione di mercato
$3.22B
Variazione (1 giorno)
-0.08%
Variazione (1 anno)
191.05%
Paese
CN
Scambia Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (2315)

Categoria

Healthcare
Rapporto P/E per Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (2315)
Rapporto P/E al 2026 TTM: 0
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Biocytogen Pharmaceuticals (Beijing) Co., Ltd., il rapporto P/E attuale (TTM) è 0. Alla fine del 2026, il rapporto P/E era 0.
Storico del rapporto P/E per Biocytogen Pharmaceuticals (Beijing) Co., Ltd. da 2026 a 2026
Rapporto P/E alla fine di ogni anno
Anno Rapporto P/E Cambia
Non abbastanza dati per le date fornite.
Rapporto P/E per aziende simili o concorrenti
Azienda P/E Ratio Differenza del P/E Ratio Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Come leggere un P/E ratio?

Il rapporto Prezzo/Utile (P/E) misura la relazione tra il prezzo delle azioni di una società e i suoi utili per azione.
Un P/E basso ma positivo indica un'azienda che genera alti profitti rispetto alla sua valutazione attuale e potrebbe essere sottovalutata. Un'azienda con un P/E negativo elevato (vicino allo 0) segnala forti perdite rispetto alla valutazione.

Le aziende con un P/E superiore a 30 o negativo sono generalmente considerate "azioni di crescita", cioè ci si aspetta che crescano o diventino redditizie.

Le aziende con un P/E positivo inferiore a 10 sono considerate "azioni di valore", ossia già molto redditizie ma con scarse prospettive di crescita.